Subtype
WHO Grade 3 Glioma
CI-CAN-00007116Explore in graph →
57 active trials1 approved drugs9 evidence items
- NCIt
- C127816
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007116Explore in graph →
Clinical trials
258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (53)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02031965 | Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery | terminated | Phase 1 | 2 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | May 30, 2016 | clinicaltrials |
| NCT01144247 | Cellular Immunotherapy Study for Brain Cancer(alloCTL) | completed | Phase 1 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 27, 2016 |
| NCT00326664 | AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2016 | clinicaltrials |
| NCT00301418 | Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma | completed | Phase 1 / Phase 2 | 11 | Northwell HealthOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01189240 | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma | terminated | Phase 1 / Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Dec 14, 2015 | clinicaltrials |
| NCT01119599 | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2015 | clinicaltrials |
| NCT00112736 | Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2015 | clinicaltrials |
| NCT01861990 | Valproic Acid in Childhood Progressive Brain Tumors | withdrawn | Phase 1 | 0 | Medical University of South CarolinaOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT00968240 | Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) | completed | Phase 1 | 30 | Northwell HealthOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT00734682 | A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 34 | University of California, San FranciscoOTHER | 1 | Jan 7, 2015 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01378481 | High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00024570 | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 60 | INSYS Therapeutics IncINDUSTRY | 1 | Nov 14, 2014 | clinicaltrials |
| NCT00884416 | Sorafenib in Newly Diagnosed High Grade Glioma | completed | Phase 1 | 17 | University Hospital, GenevaOTHER | 1 | Nov 4, 2014 | clinicaltrials |
| NCT02055196 | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00093613 | Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00650923 | Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma | completed | Phase 1 | 61 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00042991 | Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00610571 | Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | completed | Phase 1 | 62 | Katy PetersOTHER | 1 | Oct 25, 2013 | clinicaltrials |
| NCT00612651 | PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas | completed | Phase 1 | 37 | Duke UniversityOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT01269411 | RO4929097 in Treating Patients With Recurrent Invasive Gliomas | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00006773 | Bortezomib in Treating Patients With Recurrent Glioma | terminated | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00110032 | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors | terminated | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00734864 | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | withdrawn | Phase 1 | 0 | Annick DesjardinsOTHER | 1 | Nov 21, 2012 | clinicaltrials |
| NCT00272870 | Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy | terminated | Phase 1 | 1 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Aug 29, 2012 | clinicaltrials |
| NCT00089427 | IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 24 | INSYS Therapeutics IncINDUSTRY | 1 | Jul 4, 2011 | clinicaltrials |
| NCT00024557 | Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients | completed | Phase 1 | 40 | INSYS Therapeutics IncINDUSTRY | 1 | Jun 6, 2011 | clinicaltrials |
| NCT00041587 | Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 80 | INSYS Therapeutics IncINDUSTRY | 3 | Jun 6, 2011 | clinicaltrials |
| NCT00064779 | Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | completed | Phase 1 | 18 | INSYS Therapeutics IncINDUSTRY | 1 | Jun 6, 2011 | clinicaltrials |
| NCT00115440 | BNCT to Treat Glioma That Has Progressed Following Radiotherapy | completed | Phase 1 / Phase 2 | 22 | Boneca CorporationINDUSTRY | 1 | Jan 28, 2009 | clinicaltrials |
Data updated 23 days agoSource updated May 30, 2016source: clinicaltrials